ORICOric Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$142M
- 0.0% YoY
- Market cap
- $958M
- Employees
- 104
- Net debt / EBITDA
- —
- −$27M net debt
- AI in 10-K
- 1.9
- mentions per 10K words
Takeover score 1 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$5M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo91% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo1.9 per 10K words · 53rd pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$958M market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$3M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$79M | −$92M | −$111M | −$143M | −$143M | 0.1% |
| Net income | −$79M | −$89M | −$101M | −$128M | −$129M | 1.3% |
| Operating cash flow | −$60M | −$75M | −$86M | −$113M | −$111M | 1.5% |
| Capex | $939K | $2M | $849K | $1M | $712K | 40% |
| Stock-based comp | $13M | $14M | $15M | $20M | $25M | 24% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Aug 14, 2025 | SR ONE CAPITAL MANAGEMENT, LLC | SCHEDULE 13D/A | 14.9% | Passive |
| Jun 5, 2025 | SR ONE CAPITAL MANAGEMENT, LLC | SCHEDULE 13D | 5.4% | Passive |
| Dec 27, 2022 | ORBIMED ADVISORS LLC | SC 13D/A | 4.5% | Passive |
| Aug 12, 2021 | ORBIMED ADVISORS LLC | SC 13D/A | 5.9% | Passive |
| Mar 22, 2021 | ORBIMED ADVISORS LLC | SC 13D/A | 6.8% | Passive |
| Nov 18, 2020 | ORBIMED ADVISORS LLC | SC 13D/A | 7.8% | Passive |
| May 1, 2020 | ORBIMED ADVISORS LLC | SC 13D | 9.7% | Passive |
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 16
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $6M | $6M | 89 | — |
| FY2024 | $5M | $4M | 88 | — |